Subject
Pharmacology (medical),Pharmacology
Reference10 articles.
1. The roles of IL-17A in inflammatory immune responses and host defense against pathogens;Iwakura;Immunol Rev,2008
2. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial;Ferrante;Lancet,2022
3. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials;D'Haens;Lancet,2022
4. Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn's disease;Loftus;Adv Ther,2023
5. Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto-injector for subcutaneous injection;Lon;Clin Ther,2021